Search

Displaying results 5381 - 5390 of 10000 in total
  1. Drug

    Fluocortin

    go.drugbank.com/drugs/DB13223
    Experimental

    Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain .

    Categories: Corticosteroids, Moderately Potent (Group II)
  2. Drug

    Fluperolone

    go.drugbank.com/drugs/DB13491
    Experimental

    Categories: Corticosteroids, Moderately Potent (Group II)
  3. Drug

    Avasopasem manganese

    go.drugbank.com/drugs/DB16354
    Investigational

    [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19. … Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.

  4. Drug

    AB192

    go.drugbank.com/drugs/DB06111
    Experimental

    AB192 is a DPP IV enzymatic activity inhibitor.

  5. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  6. Drug

    Viper antivenom

    go.drugbank.com/drugs/DB14114
    ApprovedInvestigational

    ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation

  7. Drug

    TPI-ASM8

    go.drugbank.com/drugs/DB05572
    Investigational

    TPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.

  8. Drug

    HLX70

    go.drugbank.com/drugs/DB16509
    Investigational

    in healthy adult volunteers. … The condition targeted by HLX70 in this study is COVID-19.

  9. Drug

    KAND567

    go.drugbank.com/drugs/DB16511
    Investigational

    Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].

  10. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).[L56124, L56125, L56126]